Nektar says five abstracts accepted at ASCO meeting
Nektar Therapeutics announced last night that five of its abstracts were accepted for presentation at the Annual Meeting of the American Society of Clinical Oncology, which is being held from May 31 to June 4. The abstracts published in advance of the ASCO annual meeting were made available last night. "We are pleased to announce the presentation of five abstracts for our lead I-O investigational candidate, bempegaldesleukin, which includes important translational clinical data for the combination of bempeg with nivolumab as well as early data from an investigator-sponsored pilot study conducted in patients with heavily pre-treated, rapidly progressing and refractory sarcomas," said Stephen Doberstein, Chief Research & Development Officer at Nektar. "We are also highlighting several registrational trials underway for bempeg plus nivo in patients with melanoma and RCC. We believe bempeg has a unique and non-overlapping mechanism which synergizes with various immunotherapies, including checkpoint inhibitors, to improve the body's cancer-fighting immune response and potentially improve treatment outcomes for patients with a variety of cancers."